Subscribe
Logo small
Search

Access to innovative therapies: It's bad, but it hasn't been this good before

MedExpress Team

medexpress.pl

Published May 16, 2024 07:42

Access to innovative therapies: It's bad, but it hasn't been this good before - Header image
Thinkstock/GettyImages
Access to innovative therapies and diagnostic solutions in Poland improved again last year, mainly due to oncology drugs and those used for rare diseases. The least progress is in chronic diseases, although clinicians stress that there has been tremendous progress in this area as well in recent years.

Over the past year, access to innovative therapies and diagnostic solutions in Poland has increased by 5 points and stands at 58 points out of 100 on the KPI scale, according to the latest data collected by the Access GAP platform, which presents data on the Visegrad Group countries. The Czech Republic remains the leader, followed by Slovakia, with Poland in third place, slightly ahead of Hungary. The Association of Employers of Innovative Pharmaceutical Companies INFARMA presented the report, which consists of a comparison of the Visegrad Group countries and the Polish Refund Radar, on Wednesday.

The data is clear: access to innovative drugs and diagnostic solutions is improving in all Visegrad countries, and in Poland it has improved by 16 points over three years. In the first edition, presented in 2022 (data for 2021), the overall Access GAP index for Poland was ...

Content locked

To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.

Read also